Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197229 | 0.84 | HTR2A (0.49) | PARP1GPR119HSD11B1HDAC1NR1H2 | |
| SCHEMBL6703193 | 0.73 | PARP1 (0.51) | PARP1GPR119HSD11B1HDAC1NR1H2 | |
| SCHEMBL1930266 | 0.73 | PARP1 (0.51) | PARP1GPR119HSD11B1HDAC1NR1H2 | |
| SCHEMBL30818801 | 0.72 | PARP1 (0.54) | PARP1GPR119HSD11B1HDAC1NR1H2 | |
| SCHEMBL31472006 | 0.71 | HSD11B1 (0.79) | PARP1GPR119HSD11B1NR1H2NR1H3 | |
| SCHEMBL30607714 | 0.70 | PARP1 (0.48) | PARP1GPR119HSD11B1HDAC1NR1H2 | |
| SCHEMBL30607679 | 0.70 | HDAC1 (0.48) | PARP1GPR119HSD11B1HDAC1F13A1 | |
| SCHEMBL17229916 | 0.69 | HDAC1 (0.47) | PARP1GPR119HSD11B1HDAC1 | |
| SCHEMBL4100723 | 0.69 | PARP1 (0.54) | PARP1GPR119HSD11B1HDAC1F13A1 | |
| SCHEMBL4094782 | 0.69 | PARP1 (0.54) | PARP1GPR119HSD11B1HDAC1F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236947-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | disclosed |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2011-09-29 | — | — | US | disclosed |
| US-7977337-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | GLAXO GROUP LIMITED | 2009-02-05 | — | — | US | disclosed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | PARP1 1616/4885GPR119 213/4885HSD11B1 3976/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | PARP1 3116/4885GPR119 220/4885HSD11B1 3110/4885 |
| US-20110237792-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | PARP1 1303/4885GPR119 282/4885HSD11B1 4080/4885 |
| US-20100305107-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR7 | PARP1 1303/4885GPR119 282/4885HSD11B1 4080/4885 |
| US-20090036682-A1 | Quinoline Derivatives and Their Use as 5-HT6 Ligands | HTR6, HTR3B, HTR4 | PARP1 1616/4885GPR119 213/4885HSD11B1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.